MeSH term
Frequency | Condition_Probility | Binding Sites | 2 | 0.0 |
Cell Line | 4 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Fluorescent Antibody Technique | 6 | 0.0 |
Humans | 42 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 3 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 3 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 39 | 0.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
*Antigens, Nuclear | 28 | 19.0 |
Autoantibodies/blood/*immunology | 2 | 5.0 |
Autoantigens/*immunology | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Nuclear Proteins/*immunology | 3 | 14.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Animals | 17 | 0.0 |
Autoantigens/genetics/metabolism | 2 | 25.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 9 | 0.0 |
Time Factors | 3 | 0.0 |
Transcription Factors/*metabolism | 5 | 0.0 |
Blotting, Western | 4 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Female | 4 | 0.0 |
Immunoblotting | 4 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Peptide Library | 2 | 1.0 |
Tumor Cells, Cultured | 11 | 0.0 |
*GTP-Binding Proteins | 2 | 3.0 |
Nuclear Proteins/metabolism | 5 | 0.0 |
Autoantigens/*genetics | 6 | 8.0 |
*Evolution, Molecular | 2 | 0.0 |
Nuclear Proteins/*genetics | 5 | 0.0 |
Amino Acid Sequence | 11 | 0.0 |
Base Sequence | 12 | 0.0 |
Hela Cells | 9 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
RNA Splicing | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Autoantigens/metabolism | 4 | 9.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Ubiquitins/metabolism | 4 | 2.0 |
Interferons/pharmacology | 6 | 8.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Protein Transport | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
SUMO-1 Protein | 4 | 11.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Nuclear Proteins/*physiology | 4 | 2.0 |
Transcription Factors/*physiology | 2 | 0.0 |
3T3 Cells | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Mice | 5 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Protein Binding | 3 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Autoantigens/*metabolism | 2 | 8.0 |
Cell Compartmentation | 2 | 0.0 |
Cell Nucleus/*ultrastructure | 3 | 15.0 |
Antigens, Nuclear/*physiology | 2 | 66.0 |
Autoantigens/*physiology | 3 | 50.0 |
Cell Line, Tumor | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Nuclear Proteins/*analysis | 2 | 1.0 |
Transfection | 6 | 0.0 |
*Viral Proteins | 2 | 1.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Gene Amplification | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Neoplasm Proteins | 9 | 1.0 |
CHO Cells | 2 | 0.0 |
Interferons/*pharmacology | 3 | 4.0 |
Adult | 2 | 0.0 |
Aged | 2 | 0.0 |
Leukemia, Promyelocytic, Acute/*metabolism | 2 | 10.0 |
Middle Aged | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
*Nuclear Proteins | 3 | 0.0 |
Comparative Study | 3 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Autoantigens/biosynthesis/*genetics | 2 | 66.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Nuclear Proteins/biosynthesis/*genetics | 2 | 5.0 |
Transcription Factors/biosynthesis/*genetics | 2 | 1.0 |
Chromosome Mapping | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Liver Cirrhosis, Biliary/*immunology | 4 | 11.0 |
Cercopithecus aethiops | 2 | 0.0 |
Vero Cells | 2 | 0.0 |
Cells, Cultured | 4 | 0.0 |
